Table 1.
Demographic, Neuropsychological, and Clinical Information (Previously Reported in Salisbury et al15)
| FESz | HC | t/X 2 | P | Cohen’s d | |
|---|---|---|---|---|---|
| Age | 22.6 (5.1) | 21.1 (3.0) | 1.36 | .18 | 0.36 |
| Gender (M/F) | 19/8 | 18/9 | 0.09 | .77 | |
| SES | 31.9 (13.2) | 33.7 (13.6) | −0.51 | .61 | 0.13 |
| Parental SES | 43.1 (12.6) | 47.5 (13.5) | −1.21 | .23 | 0.34 |
| WASI | 110.4 (14.5) | 108.0 (10.7) | 0.71 | .48 | 0.19 |
| MATRICS | 42.5 (13.3) | 47.2 (8.2) | −1.54 | .13 | 0.43 |
| PANSS Total | 75.2 (14.8) | ||||
| PANSS Positive | 20.0 (5.6) | ||||
| PANSS Negative | 16.9 (4.9) | ||||
| PANSS General | 38.3 (7.5) | ||||
| PANSS TD | 11.2 (3.1) | ||||
| SAPS Global | 5.9 (2.9) | ||||
| SANS Global | 9.7 (3.1) | ||||
| Illness Duration | 73.3 (120.4) | ||||
| DUP (days) | 192.2 (201.1) | ||||
| Medication | 228.8 (147.9) |
Note: SES, socioeconomic status; WASI, Wechsler Abbreviated Scale of Intelligence; MATRICS, composite scaled t score; PANSS, Positive and Negative Syndrome Scale; TD, PANSS Thought Disorder factor; SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; DUP, duration of untreated psychosis; Medication, chlorpromazine equivalents.